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model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to
HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30–40% after 20
years (range 4–66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert
one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensiﬁed efforts are


















HIV and Herpes simplex virus type-2 (HSV2) have a synergis-
ic relationship. HIV affects HSV2 shedding, and the frequency and
uration of clinical reactivations [1–4]. HSV2, in turn, has a strong
mpact on HIV transmission and acquisition, and may also affect
he natural history of HIV infection [3,5–10]. A meta-analysis of
ongitudinal studies found HSV2 seropositivity to be associated
ith a risk ratio of HIV acquisition of 2.7 (95% conﬁdence inter-
al (CI) = 1.9–3.9) in men and 3.1 (95% CI =1.7–5.6) in women [11]
nd most cross-sectional studies have found a correlation between
SV2 and frequency and/or quantity of HIV mucosal shedding
12–14].
HSV2 prevalence and the estimated proportion of HIV infec-
ions attributable to HSV2 (population attributable fraction, PAF)
re very high in sub-Saharan Africa (Africa) and therefore HSV2
ontrol could have a substantial population-level impact on the
IV epidemic [3,11]. However, two recent randomised-controlled
rials of herpes suppressive therapy have failed to show an impact
nHIV acquisition, perhaps because of insufﬁcient herpes suppres-
iondue todrugdosageor inadequateadherence, or themechanism
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f action of acyclovir does not reduce the role of HSV2 in HIV trans-
ission [15,16]. HSV2 vaccinesmay provide amore effectivemeans
f HIV control.
An ideal prophylactic vaccinewould prevent infection, although
artially effective prophylactic vaccines may still be useful if they
hift the threshold of infection, or if they prevent or ameliorate
isease [17,18]. These vaccines could reduceHSV2 incidence by pre-
enting infection or by reducing the infectivity of an HSV2-infected
ndividual through reductions in shedding or clinical recurrences.
onversely, vaccines could increase HSV2 incidence if they reduced
ymptomatic signs of disease but had no effect on viral shedding
17,18].
Prophylactic vaccines to prevent HSV2 acquisition have been
estedwith limited success. The Chiron-gD2gB2-MF59 vaccine pro-
ided only temporary protection lasting a few months [18]. The
laxoSmithKline (GSK)-gD2-alum-MPL prophylactic vaccine had
o effect in men or HSV1 positive women, but in HSV1 seroneg-
tive women the risk of HSV2 infection and disease was reduced
19]. A further trial of the GSK vaccine in HSV1 negative women is
ngoing. However this vaccine may not be useful in Africa because
f the very high HSV1 prevalence [20].
Open access under CC BY license.Estimating the population-level impact of an HSV2 vaccine on
IV is complex because of its potential effects on both acquisition
nd transmission of HIV as well as the bi-directional relation-
hip between HIV and HSV2. Mathematical modelling can be used
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he relationship between HSV2 and HIV [21–25]. One study has
xplored the potential impact of HSV2 therapy on HIV incidence
26], but none have examined the impact of an HSV2 prophylactic
accine on HIV incidence in Africa, where interventions are most
eeded.
The aimof this paper is to explore the potential population-level
mpact of prophylactic HSV2 vaccines on HIV incidence in one low
nd one high HIV prevalence city in sub-Saharan Africa using the
TDSIM mathematical model.
. Methods
.1. Data, model and baseline model scenarios
STDSIM has been ﬁtted to population-based data collected from
our cities in Africa in 1997 and to available data on trends over
ime, as published [23,27].
STDSIM is an individual-based stochastic model that sim-
lates the natural history of, and interactions between, HIV,
SV2, syphilis, gonorrhoea, chlamydia and chancroid. It has been
escribed in detail [28,29]. STDSIM is able to simulate realistic
exual networks and heterogeneity between individuals in sexual
ehaviour and in the natural history of infection. STDSIM has pre-
iously been used to explore the impact of STI treatment and male
ircumcision for HIV-1 prevention and the heterogeneous spread
f HIV-1 in Africa [23,27,30–32].
Themodel representation of thenatural history ofHSV2, and the
nteractionbetweenHIVandHSV2,wasparameterisedbasedon the
iteraturewhere possible, and poorly knownparameter values have
een subjected to sensitivity analysis [23,27]. For simplicity, HSV2
atural history was categorised into four stages: ‘primary genital
erpes’, ‘early’, ‘middle’, and ‘late’. After ‘primary genital herpes’,
SV2 reactivations are modelled to occur in the ‘early’ and ‘middle’
tages with decreasing frequency with time since infection [33,34].
linical reactivation rates were assumed to vary widely between
ndividuals [35]. Per-contactmale-to-female (MtoFtp) transmission
robabilities for bothHIVandHSV2wereassumed tobe twice those
or female-to-male (FtoMtp) [36]. Per-contact HSV2 transmission
robabilities were assumed to be highest during ‘primary genital
erpes’ (MtoFtp = 0.29), and lower during periods of clinical reacti-
ation (MtoFtp = 0.20) [37], although one recent study showed self-
eported recurrence rateswere not associatedwithHSV2 transmis-
ion [38]. Between clinical reactivations, a low HSV2 transmission
robabilitywasassumedduring the ‘early’ (MtoFtp = 0.01) and ‘mid-
le’ (MtoFtp = 0.005) stages to account for transmissions that occur
uring sub-clinical shedding [22,25,35,39]. We assumed no HSV2
ransmission or clinical reactivations during the ‘late’ stage.
HSV2 clinical reactivation was assumed to increase HIV acqui-
ition and transmission. The magnitude of the per-contact HSV2
ofactor effects onHIV acquisition and transmissionwere chosen to
e at the lower endof the estimated range for genital ulcers (3–300)
o account for possible residual confounding due to common risk
ehaviours that may inﬂate estimates [40] and have been subject
o sensitivity analyses [23]. The cofactor effect was assumed to be
he same for HIV acquisition and transmission and was 25 during
rimary genital herpes and 10 during recurrent HSV2 clinical reac-
ivations. Although biologically plausible [41], no increase in the
isk of HIV acquisition or transmission was assumed for the peri-
ds of sub-clinical shedding between clinical reactivations, due to
he lack of deﬁnitive data. This and other poorly known assump-
ions were subjected to sensitivity analysis. We have previously
hown that themagnitude of these per-contact cofactor effects give
ncidence rate ratios for the association between HIV and HSV2
revalence, and PAFs of HIV incidence associatedwith HSV2, in line
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tive risks of HSV2 infection for HIV incidence in Cotonou were 5.8
n males (data =5.4, 2.2–13) and 6.6 in females (data =7.0, 2.9–17),
nd in Kisumu 3.5 in males (data =9.0, 5.1–16) and 4.4 in females
data =4.7, 3.0–7.5) [42,43]. The simulated PAFs [31] for adults over
yearswere around45% in Cotonou and 35% inKisumu [23],within
he range estimated in a meta-analysis that showed that 38–60%
f new HIV infections in African women and 8–49% of new HIV
nfections in men could be due to HSV2 [11], depending on HSV2
revalence levels that ranged from29% to 71% inwomen and5–53%
n men [20]. Simulated PAFs were higher in Cotonou than Kisumu
rimarily because of lower rates of other cofactor STIs in Cotonou
23].
Other model parameter values, for the demography, sexual
ehaviour and natural history of the other STIs and their interac-
ion with HIV were as reported in our previous publication [27],
xcept that the mean survival time from HIV infection to death
as increased from 10 to 11 years in line with the ﬁndings of
recent meta-analysis [44], and an additional increase in con-
om use rates was simulated in 2000 (to 40% of casual and sex
orker contacts) in Kisumu to ﬁt recent falls in HIV prevalence (pc
.Cohen, 20/4/2007). Per-contact cofactor effects of other STIs on
IV susceptibility and infectivity were assumed to be 25 for chan-
roid, 7.5 for primary syphilis, and 3 for gonorrhoea and chlamydia
nfection. Lack-of-male-circumcision was assumed to double the
er-contact probability of male acquisition of HIV, syphilis and
hancroid [45,46]. In the model, in a sexual encounter in which
here was more than one cofactor present, only the highest of the
elevant cofactor effects was assumed to act on the probability
f HIV transmission in that sexual act, because it is unclear how
ofactors combine to increase transmission [47].
In this paper we present results for two cities. Cotonou, Benin
epresents an HIV epidemic highly concentrated among female sex
orkers (FSWs) and their clients, while Kisumu, Kenya represents a
ore generalisedHIVepidemic typical ofmanycountries inEastern
nd Southern Africa [27].
.2. Simulated interventions
As the existing vaccines are unlikely to be efﬁcacious in Africa,
e explored the impact of a potential prophylactic vaccine. HSV2
accination was targeted at a proportion of HSV2-uninfected indi-
iduals who were simulated to beneﬁt for a ﬁxed duration of time.
e simulated three primary scenarios in which the vaccine was
ssumed to (i) reduce susceptibility to HSV2 acquisition, (ii) reduce
SV2 reactivation (frequency and duration of clinical reactivation
nd HSV2 infectivity during and between clinical reactivations), or
iii) both.
In each of these three primary scenarios we assumed three
strengths’ of the effect of the vaccine. In the ‘weak, ‘moderate’ and
strong’ vaccine efﬁcacy scenarios, the values of parameters listed
bove were reduced by either 30%, 75% or 90%, respectively. For
xample, in the ‘weak vaccine efﬁcacy (iii)’ scenario, we assumed a
0% reduction in susceptibility toHSV2 acquisition, a 30% reduction
n clinical reactivation duration, a 30% reduction in clinical reacti-
ation frequency, and a 30% reduction in HSV2 infectivity during
nd between HSV2 clinical reactivations.
We assumed a linear increase in the prevalence of vaccination
ver5years from0% to50%, 0% to70%or0% to90%of targetedHSV2-
ninfected individuals. We simulated routine annual vaccination
f 14-year olds (chosen as the oldest children reliably in-school),
nd an initial ‘catch-up’ campaign targeting 15–29-year olds. Both
roups were subjected to the linear increase in vaccination preva-
ence. We simulated two other scenarios in which (a) the vaccine
as only efﬁcacious in females, and (b) the catch-up campaign was
mitted.

















3ig. 1. Observed (95% CI) and simulated prevalence of HIV and HSV2 by age and gen
emale. Note difference in y-axis scale used on HIV prevalence graphs. Gen. pop. = g
We simulated separate scenarios in which the duration of the
accine effect was assumed to be 5 years, 10 years or lifelong.
e assumed all individuals would receive only one course of
mmunisation during their lifetime. The simulated intervention
as ongoing from 1/1/2008. Results were based on means over
00–1000 simulations.
.3. OutcomeWe present the percentage reduction in annual HSV2 and HIV
ncidence in adults aged 15–49-year old after 10 and 20 years, cal-
ulated by comparing intervention and baseline scenarios, and the




H1997 and over time in Cotonou and Kisumu (adults aged 15–49 years). M, male; F,
population. ANC=ante-natal clinic.
.4. Sensitivity analysis
We assessed the robustness of our ﬁndings to key baseline and
ntervention model parameter values known to affect impact. Full
etails are shown in the supporting information, online.
. Results
.1. Baseline scenarioFig. 1 shows that a good ﬁt of the model simulations to data for
emography, sexual behaviour and epidemiology of the two pop-
lations was achieved, as published [23,27]. The simulated PAF for
SV2 among 15–49-year olds over 2008–2013 was 45% in Cotonou
E.E. Freeman et al. / Vaccine 27 (2009) 940–946 943

















































s0%), vaccine duration of effect (5 years, 10 years, lifelong), vaccine effect (susceptib
imulated in addition to routine annual vaccination of 14-year olds, three scenarios
accine efﬁcacy. See Section 2 for full details. M, male; F, female.
nd 35% in Kisumu. Full details of the baseline scenario are shown
n the supporting information, online.
.2. Interventions
The effects of the interventions in terms of percentage reduction
n HSV2 and HIV incidence after 10 and 20 years in the two cities
re shown in Figs. 2 and 3. The point estimates (black-markers)
esult from simulations assuming ‘moderate’ (75%) vaccine efﬁ-
acyoptions forall parameters, and theplausiblebound (grey-lines)
rom assuming ‘weak’ (30%) or ‘strong’ (90%) values. For clarity, it
as assumed that there are no other changes in interventions, and
o antiretroviral therapy, over the period.
Prophylactic vaccination that only reduced HSV2 susceptibility
ended to have a slightly larger impact on HSV2 incidence than
accination that only reduced HSV2 reactivation (Fig. 2). Vaccina-
ion that reduced both HSV2 susceptibility and reactivation had a
lightly larger effect on HSV2 incidence, leading to reductions in
SV2 incidence of 12–98% across both cities after 20 years.
Conversely, a vaccination that only reduced susceptibility to
SV2 infectionwaspredicted tohavea slightly smaller effectonHIV
ncidence than a vaccination that only reduced HSV2 reactivation
Fig. 3). Again vaccination that reduced both HSV2 susceptibility
nd reactivation had a slightly larger effect on HIV incidence, lead-
ng to reductions in HIV incidence of 4–66% across both cities after
0 years.
As expected, the impact on HIV incidence increased with
accination efﬁcacy, duration of effect, and coverage (Fig. 3). A vac-
ination campaign that achieved 70% coverage over 5 years using





tr reactivation or both), and whether a ‘catch-up’ campaign of 15–29-year olds was
own corresponding to the ‘weak’ (30%, ⊥), ‘moderate’ (75%, ) and ‘strong’ (90%, )
usceptibility and reactivation in both sexeswould reduceHIV inci-
ence by around 30–40% across both cities after 20 years.
Vaccination that was only efﬁcacious in women would have
round two-third of the impact on HIV incidence of vaccination
hat was efﬁcacious in both genders (Fig. 3). Omitting an ini-
ial ‘catch-up’ campaign covering 15–29-year olds reduced impact.
owever, increasing the age range to include all HSV2-unifected
ndividuals aged 30+ years had little additional effect on HIV (not
hown). The impact of vaccination on incidence over 10 or 20 years
Figure S1/S2) was smaller than the corresponding impact on inci-
ence after 10 and 20 years (Figure 1/2) because of the increasing
ontribution of indirect effects over time.
The number of vaccinations required to avert one HIV infection
asmuch lower inKisumu thanCotonou, because of the higherHIV
revalence in Kisumu, but it fell over time in both sites because of
ngoing indirect effects (i.e., preventing one infectionnowprevents
ultiple infections in the future) (Fig. 4). Over 20 years, a vaccina-
ioncampaign that achieved70%coverageover5yearsusingamod-
ratelyeffectivevaccinewith10-yeardurationonsusceptibility and
eactivation in both sexes would avert one HIV infection for every
0 vaccinations in Kisumu and every 58 vaccinations in Cotonou,
espectively. Over 20 years, in most scenarios fewer than 100 vac-
inations were required to avert one HIV infection (not shown).
The effect of the interventions on prevalence after 20 years was
maller for HSV2 than HIV despite the larger impact of the inter-
entions on HSV2 incidence, because HIV-infected individuals are
emoved more quickly from the population by AIDS mortality. Vac-
ination that reduced both HSV2 susceptibility and reactivation
educed HSV2 and HIV prevalence by 3–35% and 5–53%, respec-
ively, across both cities after 20 years.
944 E.E. Freeman et al. / Vaccine 27 (2009) 940–946














tig. 3. Impact of HSV2 prophylactic vaccines on HIV incidence after 10 and 20 year
0%), vaccine duration of effect (5 years, 10 years, lifelong), vaccine effect (susceptib
imulated in addition to routine annual vaccination of 14-year olds, three scenarios
accine efﬁcacy. See Section 2 for full details. M, male; F, female.
.3. Sensitivity analysis
For HSV2 incidence, the sensitivity analysis of the effect of
hanging each intervention parameter value individually shows
hat the effect on HSV2 susceptibility had the largest effect. For
IV incidence, the effects of the vaccine on HSV2 susceptibility,
linical reactivation duration and clinical reactivation frequency





ig. 4. Number of vaccinations per HIV infection averted over 10 and 20 years, by city (all
ver 5 years in 14–29-year oldsusing a vaccinewith10-year durationof effect on susceptibi
o the ‘weak’ (30%, ), ‘moderate’ (75%, ) and ‘strong’ (90%, ⊥) vaccine efﬁcacy. See Sectiity (adults aged 15–49 years). For each combination of vaccine coverage (50%, 70%,
r reactivation or both), and whether a ‘catch-up’ campaign of 15–29-year olds was
own corresponding to the ‘weak’ (30%, ⊥), ‘moderate’ (75%, ) and ‘strong’ (90%, )
ogether, the three reactivation effects had a larger impact on HIV
ncidence than the susceptibility effect alone (Fig. 3).
Figure S4 shows the sensitivity of the results to the baseline
arameter value assumptions made about cofactor effects in dif-
erent stages of HSV2 infection. As expected, these changes had no
mpact on HSV2 incidence.
Assuming a between-clinical reactivation cofactor effect, while
eeping the PAF for HSV2 constant by reducing the cofactor
ages). The modelled scenario assumes an increase from 0% to 70% vaccine coverage
lity and reactivation inmales and females. Three scenarios are showncorresponding
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ffects during clinical reactivation, reduced the impact of vaccina-
ion on HIV incidence in both cities. This is because the vaccine
as assumed not to reduce between-clinical reactivation cofac-
or effects, so if this contributed to the total cofactor effect, the
otential beneﬁt of simulated vaccination was reduced.
ChangingHSV2clinical reactivation cofactorshad larger impacts
n theeffects of vaccinationonHIV incidencebecause they changed
he PAF of HIV incidence associated with HSV2 (Figure S4). How-
ver, doubling or halving HSV cofactor effects does not provide as
ood a ﬁt to the observed relative risks for the association of HSV2
nd HIV [43].
. Discussion
This study shows that HSV2 vaccination could theoretically
educe HIV incidence sufﬁciently for a substantial public health
mpact. While the largest impact on HIV incidence would be
chieved if vaccination reduced both HSV2 susceptibility and reac-
ivation, our results suggest that most of this impact would be
chieved by a vaccine that only reduced susceptibility or reacti-
ation. A larger relative impact was seen in Cotonou, the lower HIV
revalence city, because of the higher PAF for HSV2, although more
accinations would be required to avert one infection in this lower
IV prevalence population.
In addition to the direct beneﬁt of reducing HSV2-related mor-
idity, our results suggest that high efﬁcacy HSV2 vaccines could
ave a substantial impact on population-level HIV incidence, and
ower efﬁcacy vaccines could still have a useful impact on HIV
f given at high coverage. Vaccines inducing lifelong protection
ould be easier to implement because vaccination could be inte-
rated into existing childhood vaccination schedules. If vaccines
ad shorter durations of effect they would need to be targeted at
ge groups just before their highest risk of HSV2 infection, such as
omen under 15 years and slightly older men.
The impact of HSV2 vaccination on HIV incidence and preva-
ence in themodel is directlydependentupon theassumedstrength
f the relationship between HSV2 and HIV. The simulated relative
isks and PAFs were in line with empirical data, but the failure of
he two recent randomised-controlled trials of herpes suppressive
herapy to showan impact onHIV acquisition [15,16] has cast doubt
n this relationship [48]. If we have over- or under-estimated the
AF of HIV incidence associated with HSV2, then we may have
ver- or under-estimated the potential impact of vaccination on
IV incidence.
As our sensitivity analysis showed, the impact of vaccina-
ion was somewhat dependent on assumptions about the relative
mportance of clinical and sub-clinical reactivations for HIV trans-
ission (Figure S4). However, vaccination might also reduce any
ub-clinical cofactor effect so the sensitivity of our results to this
ncertainty may have been overestimated. If sub-clinical reactiva-
ions were more important than we assumed and their frequency
anes more slowly than we assumed for clinical reactivations,
hen vaccine impact may take longer to appear, because preva-
ent HSV2 cases would continue to increase HIV transmission for
onger after HSV2 infection. The slightly larger predicted impact of
educedHSV2 reactivation compared toHSV2 susceptibility should
e treated with caution because it depends on the assumed effects
f the potential vaccine. Understanding of HSV2 natural history
ontinues to improve from empirical work and should be incor-
orated into future modelling studies.It is important to note that the impact of a prophylactic vaccina-
ion campaign onHIV incidence over a period of timewill always be
maller than the simulated PAF forHSV2over the same timeperiod,
ecause prophylactic vaccinationwill not have a direct effect on the
arge proportion of individuals that are already HSV2-infected. For27 (2009) 940–946 945
his a therapeutic vaccination or HSV therapy is required. Results
f a trial of the impact of HSV2 therapy on HIV transmission will be
vailable in 2009.
Speciﬁc assumptions about the action and mechanism of the
nterventions on HSV2 were informed by the literature wherever
ossible, but as this intervention was hypothetical, a wide range
f values was explored. Even with these ranges, it is possible that
ur assumptions may have been overly optimistic in terms of some
arameters, such as being able to vaccinate at least 50% of 14–29-
ear olds over 5 years, and being able to achieve a vaccine ‘strength’
t least as large as a 30% reduction in susceptibility, clinical reacti-
ation duration and frequency, and HSV2 infectivity.
Themost optimistic estimates suggests anHSV2 vaccinewill not
e available for at least 10 years (pcA.Wald, 8/4/2008).Most African
ountries should be providing affordable antiretroviral treatment
ART) within this period. ART reduces HSV2 reactivation in indi-
iduals with ART-induced reversal of immunosuppression and this
s likely to reduce the impact of a potential HSV2 vaccine. How-
ver, even at high coverage, ART may not reduce HIV incidence in
frica [49] and therefore a HSV2 vaccine could still be a useful HIV
revention intervention.
We have presented the reductions in HIV incidence and preva-
ence that could be achieved through the introduction of a
ypothetical HSV2 vaccination in certain scenarios. Should a vac-
ine become available, the real-world impact of scaled-up HSV2
nterventions would be tempered by logistical constraints, but
SV2 vaccination has considerable potential as an HIV preventive
ntervention. Intensiﬁed efforts are needed to develop an effective
accine against HSV2.
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